PMID- 22040989
OWN - NLM
STAT- MEDLINE
DCOM- 20121206
LR  - 20161018
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 19
IP  - 5
DP  - 2011 Oct
TI  - [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its 
      clinical application].
PG  - 1283-8
AB  - This study was aimed to investigate the clinical value of detecting BCR/ABL 
      fusion gene by fluorescence in situ hybridization (FISH). The conventional 
      cytogenetic test and detection of BCR/ABL fusion gene by FISH for bone marrow of 
      patients with newly diagnosed chronic myeloproliferative disease or 
      myelodysplastic and myeloproliferative disorders, acute lymphocytic leukemia and 
      chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell 
      transplantation were carried out. The results showed that (1) out of 46 newly 
      diagnosed as chronic myeloproliferative disease or myelodysplastic and 
      myeloproliferative disorders, 22 cases were diagnosed as CML, the FISH detection 
      showed all positive (100%), while cytogenetic test showed 86.4% (19/22) positive, 
      in the other 24 patients who were diagnosed as other chronic myeloproliferative 
      disease or myelodysplastic and myeloproliferative disorders, BCR/ABL fusion gene 
      all were be detected as negative 100% by FISH, while the cytogenetic test of bone 
      marrow in 3 cases supported the diagnosis of CML, and the diagnosis of 
      myelodysplastic disorder in 1 case; (2) in 3 out of 7 acute lymphocytic leukemia 
      cases the BCR/ABL fusion gene could not be detected by FISH; (3) the BCR/ABL 
      fusion gene could be detected by FISH in 2 cases of CML received allogeneic 
      hematopoietic stem cell transplantation, with abnormal threshold 6.5% and 1.2% 
      respectively. It is concluded that the detection of BCR/ABL fusion gene by FISH 
      is sensitive and reliable, which is very important for the diagnosis and 
      differential diagnosis of chronic myeloproliferative disorders, myelodysplastic 
      and myeloproliferative disease, as well as definite diagnosis of Ph(+) acute 
      lymphoblastic leukemia. This method also has an important significance for 
      monitor of minimal residual disease in CML patients received allogeneic 
      hematopoietic stem cell transplantation.
FAU - Zhou, Rui-Lian
AU  - Zhou RL
AD  - Department of Hematology, Guangxi Zhuang Autonomous Region People Hospital, 
      Nanning, China.
FAU - Mo, Yao-Xi
AU  - Mo YX
FAU - Lan, Mei
AU  - Lan M
FAU - Lin, Jin-Ying
AU  - Lin JY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Female
MH  - Fusion Proteins, bcr-abl/*genetics
MH  - Genes, abl
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Leukemia/*diagnosis/genetics
MH  - Male
MH  - Middle Aged
MH  - Myeloproliferative Disorders/*diagnosis/genetics
MH  - Young Adult
EDAT- 2011/11/02 06:00
MHDA- 2012/12/10 06:00
CRDT- 2011/11/02 06:00
PHST- 2011/11/02 06:00 [entrez]
PHST- 2011/11/02 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 1009-2137(2011)05-1283-06 [pii]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1283-8.